Precision Medicine in Soft Tissue Sarcoma Treatment.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Soft tissue sarcoma (STS) encompasses diverse histological subtypes with varying mutation profiles and treatment sensitivities.
• Current clinical trials often group diverse STS subtypes, hindering efficacy comparisons and treatment conclusions.

Purpose of the Study:

• To review the progress and challenges in developing precision therapy for soft tissue sarcoma.
• To highlight the need for integrating genomic data into clinical treatment strategies for STS.

Main Methods:

• Review of current literature on soft tissue sarcoma (STS) clinical trials and precision medicine approaches.
• Analysis of the role of cancer genome profiling in identifying targetable mutations for STS.

Main Results:

• STS heterogeneity complicates treatment efficacy assessment across broad clinical trials.
• Targeted therapies and precision medicine offer promising avenues for specific STS subtypes and mutations.

Conclusions:

• Developing effective targeted therapies for rare STS subtypes requires novel clinical trial designs and preclinical mutation detection.
• Connecting clinical genomic profiling data to optimal treatment strategies is essential for advancing precision therapy in STS management.